ArticleInternational journal of molecular sciences2026
Construction of a Neoantigen Prognostic Model for Gastric Adenocarcinoma Based on Multi-Omics Data Mining and the Design of mRNA Vaccines and Targeted Drugs.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrative bioinformatics and machine learning reveal hub genes and immune signatures bridging type 2 diabetes mellitus, fracture susceptibility, and osteoblast differentiation dysfunction.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study systematically explored immune targets in gastric adenocarcinoma (GAC) suitable for mRNA vaccine development. Based on multi-omics data from public databases, we first screened a set of potential tumor-associated antigen genes. Subsequently, using ten machine learning algorithms, we constructed 101 prognostic models and, through optimization and comparison, selected the Random Survival Forest (RSF) method to establish a clinical prognostic model for GAC consisting of seven genes (TYMP, IFGN, ITGAX, GBP5, GBP4, STAT1, CD84). At both the genetic and protein levels, these genes were closely associated with the antigen presentation process, suggesting the potential functional role of this model in antigen presentation. Further analysis of the immune infiltration characteristics in GAC preliminarily revealed its possible immune evasion mechanisms. Building on this, we designed candidate mRNA vaccine templates for GAC using the mRNAdesigner platform. Additionally, this study investigated the potential roles of the above seven genes in GAC progression and screened small-molecule compounds targeting these genes. Molecular dynamics simulations (MD) were performed to verify the binding stability between these compounds and their corresponding proteins. This study comprehensively simulated the tumor microenvironment (TME) and antigen presentation process in GAC, evaluated the clinical translation potential of the neoantigen prognostic model and its predictive value for immunotherapy, and provided a preliminary design scheme for an mRNA vaccine against GAC. The findings offer new evidence for identifying immune therapy targets in GAC and are expected to advance the development of immunotherapy strategies for GAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.